HIV
HIV is a chronic condition that continues to represent a significant challenge for healthcare systems across the region. At ELEA EXELTIS, we specialize in the development and provision of therapies for the treatment of HIV, supporting healthcare professionals in different countries and contributing to improving patients’ life expectancy and quality of life at a regional level.
| BRAND NAME | ACTIVE INGREDIENT | INDICATION | COMMERCIALIZATION |
|---|---|---|---|
|
Benjor
|
Dolutegravir | Combination therapy for HIV infection. |
 
|
|
Benjor Dolutegravir Combination therapy for HIV infection. |
|||
|
Drivelea
|
Abacavir + Dolutegravir + Lamivudine | Treatment of HIV-positive patients who are HLA-B*5701 negative and without hepatitis B infection. |
|
|
Drivelea Abacavir + Dolutegravir + Lamivudine Treatment of HIV-positive patients who are HLA-B*5701 negative and without hepatitis B infection. |
|||